Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC) (PREMDIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02518672
Recruitment Status : Terminated
First Posted : August 10, 2015
Last Update Posted : October 4, 2017
Sponsor:
Collaborators:
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Solutex (Spain)
Information provided by (Responsible Party):
SCF Pharma

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : March 2016
  Actual Study Completion Date : November 2016
Publications of Results:
Other Publications:
Fortin S, Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof, US819690, 2012, US8222295, 2012.
Fortin S, Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof, CA2672513, 2008, CA2677670, 2010, US8119690, 2011.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):